Spark Biomedical Receives $217K NIH Grant to Help Opioid-Addicted Newborns
This is some text inside of a div block.
FUNDS TO VALIDATE TRANSCUTANEOUS AURICULAR NEUROSTIMULATION FOR RELIEVING WITHDRAWAL SYMPTOMS IN INFANTS BORN WITH NEONATAL ABSTINENCE SYNDROME (NAS) Dallas, TX, October 18, 2019 — Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative. The grant (1R43DA050360-01) will be used to validate the use of neurostimulation to relieve withdrawal symptoms in infants born with neonatal abstinence syndrome (NAS).
